Latest Continuous Disclosure News

Hawk Resources has launched an options offer following a $3 million placement, aiming to fund exploration at its scandium and copper projects in Australia and the US.

HitIQ Limited attributes recent share price and volume spikes to a recent $1.4 million private placement and investor buying, denying any undisclosed material information.

Resimac Group Ltd (ASX:RMC) has explained the late filing of a director’s change of interest notice as an administrative oversight and plans refresher training to reinforce compliance.

Axel REE is progressing its low-cost in situ recovery (ISR) rare earth strategy in Brazil with field trials planned at its Woolrich deposit, while confirming ongoing assay programs with no undisclosed material information.

Titanium Sands Limited (ASX:TSL) has launched a fully underwritten offer of up to 242.7 million New Options to holders of its expired TSLOA Options, aiming to raise approximately $243,000 before expenses. The offer includes a substantial bonus component and options allocated to CPS Capital as fees for managing a $1.2 million loan.

Audalia Resources has secured $450,000 through a placement of 15 million shares at 3 cents each, aiming to push its Medcalf project closer to production while maintaining working capital.

Advent Energy, in which BPH Energy holds a 35.81% stake, will challenge a Federal Court judgment on the PEP11 gas exploration permit, prolonging uncertainty over a key NSW offshore asset.

Advent Energy, in which MEC Resources holds a 37.95% stake, will challenge a Federal Court judgment on the PEP11 offshore gas exploration permit, with its subsidiary Asset Energy leading the appeal.

Algorae Pharmaceuticals has been appointed as a supplier under a NSW Health public hospital supply contract, marking a strategic milestone despite uncertain immediate revenue impact.

Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.

Nimy Resources (ASX: NIM) responds to ASX query following a sharp share price fall, confirming pending assay results from recent sampling but no undisclosed information explaining the trading.

CD Private Equity Fund I (ASX:CD1) posted a net loss of $6.96 million for the year ended 31 March 2026, driven by a $5.14 million fair value decline in its US private equity holdings and significant foreign exchange pressures. Despite near-term setbacks, the Fund has delivered an 8.3% post-tax annual return since inception.